Biotest Has 300 Million Euros for Acquisitions, Boersen Reports

Biotest AG (BIO) may spend as much as 300 million euros ($379 million) on acquisitions, Boersen-Zeitung reported, citing Chief Financial Officer Michael Ramroth.

Targets may include makers of clotting agents, the newspaper cited the CFO as saying.

To contact the reporter on this story: Cornelius Rahn in Frankfurt at crahn2@bloomberg.net

To contact the editor responsible for this story: Kenneth Wong at kwong11@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.